[{"id":"3875d166-2701-445e-aa30-32ca8986f0a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03092518","created_at":"2021-01-18T15:14:06.092Z","updated_at":"2025-02-25T14:01:14.625Z","phase":"Phase 2","brief_title":"Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology","source_id_and_acronym":"NCT03092518","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • mitomycin • Jelmyto (mitomycin urothelial gel)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 06/05/2017","start_date":" 06/05/2017","primary_txt":" Primary completion: 04/05/2024","primary_completion_date":" 04/05/2024","study_txt":" Completion: 07/24/2024","study_completion_date":" 07/24/2024","last_update_posted":"2025-02-19"},{"id":"b3d6c3c2-daaa-494a-aacb-7469cd76f192","acronym":"","url":"https://clinicaltrials.gov/study/NCT04929028","created_at":"2021-06-18T23:52:29.721Z","updated_at":"2025-02-25T16:32:30.069Z","phase":"Phase 2","brief_title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","source_id_and_acronym":"NCT04929028","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • PD-1 • IFNG • CD4","pipe":" | ","alterations":" PD-1 expression","tags":["PD-L1 • PD-1 • IFNG • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • capecitabine • mitomycin • Jelmyto (mitomycin urothelial gel) • fluorouracil topical • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/09/2022","start_date":" 08/09/2022","primary_txt":" Primary completion: 09/15/2029","primary_completion_date":" 09/15/2029","study_txt":" Completion: 09/15/2029","study_completion_date":" 09/15/2029","last_update_posted":"2025-02-07"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"25d363db-b73d-42b4-a08a-717568224b15","acronym":"THOR-2","url":"https://clinicaltrials.gov/study/NCT04172675","created_at":"2021-01-18T20:21:16.432Z","updated_at":"2025-02-25T17:00:18.386Z","phase":"Phase 2","brief_title":"A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)","source_id_and_acronym":"NCT04172675 - THOR-2","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Balversa (erdafitinib) • mitomycin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 02/28/2020","start_date":" 02/28/2020","primary_txt":" Primary completion: 07/12/2024","primary_completion_date":" 07/12/2024","study_txt":" Completion: 03/03/2025","study_completion_date":" 03/03/2025","last_update_posted":"2025-02-03"},{"id":"0ce065b0-7320-4b49-acc1-1b38bcc23ffc","acronym":"SHIELD-RT","url":"https://clinicaltrials.gov/study/NCT03775265","created_at":"2021-01-18T18:40:31.838Z","updated_at":"2024-07-02T16:34:37.434Z","phase":"Phase 3","brief_title":"Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT03775265 - SHIELD-RT","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • gemcitabine • 5-fluorouracil • mitomycin • Jelmyto (mitomycin urothelial gel) • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 475","initiation":"Initiation: 06/03/2019","start_date":" 06/03/2019","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-06-07"},{"id":"2dbfdc25-9473-428b-8cab-86480643f58c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04107077","created_at":"2021-01-18T20:05:06.273Z","updated_at":"2024-07-02T16:35:03.848Z","phase":"Phase 2","brief_title":"Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer","source_id_and_acronym":"NCT04107077","lead_sponsor":"University of Chicago","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • mitomycin"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 03/14/2024","start_date":" 03/14/2024","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-05-14"},{"id":"b7689df4-b427-4095-b20c-3a82dc44a877","acronym":"","url":"https://clinicaltrials.gov/study/NCT04858009","created_at":"2021-04-23T21:52:41.728Z","updated_at":"2024-07-02T16:35:22.931Z","phase":"Phase 2","brief_title":"Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis","source_id_and_acronym":"NCT04858009","lead_sponsor":"Mayo Clinic","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • albumin-bound paclitaxel • mitomycin • Jelmyto (mitomycin urothelial gel)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/05/2024","start_date":" 01/05/2024","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-01-19"},{"id":"9c93d3e6-0a48-47ce-8cc8-e7790efb5f24","acronym":"RADIANCE","url":"https://clinicaltrials.gov/study/NCT04230759","created_at":"2021-01-18T20:34:57.535Z","updated_at":"2024-07-02T16:35:27.297Z","phase":"Phase 2","brief_title":"Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group","source_id_and_acronym":"NCT04230759 - RADIANCE","lead_sponsor":"Goethe University","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • 5-fluorouracil • mitomycin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 01/07/2020","start_date":" 01/07/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2023-12-04"},{"id":"67165832-27ab-4477-9f16-65916959f5b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04166318","created_at":"2021-01-18T20:19:47.273Z","updated_at":"2024-07-02T16:35:45.235Z","phase":"Phase 2","brief_title":"Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study","source_id_and_acronym":"NCT04166318","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • capecitabine • mitomycin • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 252","initiation":"Initiation: 01/02/2020","start_date":" 01/02/2020","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2023-06-22"},{"id":"6f671258-3f72-476e-bdfe-fe51bfe4e3fe","acronym":"WUHIPEC02","url":"https://clinicaltrials.gov/study/NCT04845490","created_at":"2021-04-15T12:52:58.589Z","updated_at":"2024-07-02T16:36:16.873Z","phase":"Phase 2","brief_title":"Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy","source_id_and_acronym":"NCT04845490 - WUHIPEC02","lead_sponsor":"Wuhan Union Hospital, China","biomarkers":" CD8 • IFNG • TNFA • CD4 • IL2","pipe":"","alterations":" ","tags":["CD8 • IFNG • TNFA • CD4 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e mitomycin • lobaplatin (D19466)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 201","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2022-02-21"},{"id":"7b163cbb-b2e0-4d15-a210-8f47d6b36cc0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04747717","created_at":"2021-02-10T14:55:59.163Z","updated_at":"2024-07-02T16:36:34.739Z","phase":"","brief_title":"Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer","source_id_and_acronym":"NCT04747717","lead_sponsor":"N.N. Petrov National Medical Research Center of Oncology","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • mitomycin"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/01/2020","start_date":" 10/01/2020","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2021-02-11"},{"id":"898b7e0b-12e9-47c5-a5de-01086b746d0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00386399","created_at":"2021-01-18T01:20:36.473Z","updated_at":"2024-07-02T16:37:08.997Z","phase":"Phase 2","brief_title":"Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene","source_id_and_acronym":"NCT00386399","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" BRCA2","pipe":" | ","alterations":" BRCA2 mutation","tags":["BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e mitomycin"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2006","start_date":" 10/01/2006","primary_txt":" Primary completion: 02/01/2008","primary_completion_date":" 02/01/2008","study_txt":" Completion: 02/01/2008","study_completion_date":" 02/01/2008","last_update_posted":"2018-07-12"},{"id":"e13b22cb-c9bc-4b41-8cf4-5adfe5054756","acronym":"","url":"https://clinicaltrials.gov/study/NCT00183885","created_at":"2021-01-18T00:37:25.242Z","updated_at":"2024-07-02T16:37:10.735Z","phase":"Phase 2","brief_title":"A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma","source_id_and_acronym":"NCT00183885","lead_sponsor":"University of Southern California","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • mitomycin"],"overall_status":"Unknown status","enrollment":" Enrollment 76","initiation":"Initiation: 10/18/2004","start_date":" 10/18/2004","primary_txt":" Primary completion: 05/28/2013","primary_completion_date":" 05/28/2013","study_txt":" Completion: 05/28/2019","study_completion_date":" 05/28/2019","last_update_posted":"2018-05-16"},{"id":"c21a39a8-1aac-41c1-b472-41ac2993c201","acronym":"","url":"https://clinicaltrials.gov/study/NCT01017640","created_at":"2021-01-18T03:59:27.264Z","updated_at":"2024-07-02T16:37:30.730Z","phase":"Phase 1","brief_title":"Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors","source_id_and_acronym":"NCT01017640","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • BRCA • FANCD2","pipe":" | ","alterations":" BRCA mutation","tags":["ER • BRCA • FANCD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e veliparib (ABT-888) • mitomycin"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 10/01/2009","start_date":" 10/01/2009","primary_txt":" Primary completion: 05/01/2016","primary_completion_date":" 05/01/2016","study_txt":"","study_completion_date":"","last_update_posted":"2016-07-11"}]